Exhibit 99.1 Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results Data presented at AACR and ASCO provide further validation of the potential of Bicycle technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D. Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030 CAMBRIDGE, Englan ...